title: IFN-beta treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing-remitting multiple sclerosis.
abstract: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system probably mediated by Th1 lymphocytes. IFN-beta is an established therapy for relapsing MS patients, although the mechanisms underlying its efficacy are yet to be well characterized. We determined IL-2 production, CD25 expression and T-cell proliferation from relapsing-remitting MS patients before and three months after starting therapy. A decrease in the percentage of CD80-induced IL-2-producing cells was observed after in vivo IFN-beta treatment. These data support that one of the immunomodulatory effects of IFN-beta treatment in MS may be a limitation of the autoimmune response modifying the CD80:CD28/CTLA-4 pathway.
authors.affiliation: Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. cespejo@vhebron.net
authors.forename: C
authors.initials: C
authors.lastname: Espejo
authors.forename: L
authors.initials: L
authors.lastname: Brieva
authors.forename: G
authors.initials: G
authors.lastname: Ruggiero
authors.forename: J
authors.initials: J
authors.lastname: Río
authors.forename: X
authors.initials: X
authors.lastname: Montalban
authors.forename: E M
authors.initials: EM
authors.lastname: Martínez-Cáceres
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D000818:Animals; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000378:metabolism*; D018122:B7-1 Antigen / Q000494:pharmacology; D018106:CD28 Antigens / Q000378:metabolism*; D060908:CTLA-4 Antigen; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000378:metabolism*; D008297:Male; D034801:Mastocytoma; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D000943:Antigens, Differentiation; D018122:B7-1 Antigen; D018106:CD28 Antigens; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D007376:Interleukin-2; D016899:Interferon-beta